GLP-1 agonists have taken the pharma world by storm, and Novo Nordisk has been at the forefront of it all thanks to ...

Drugs used to treat diabetes and obesity, or GLP-1 (Glucagon-like peptide-1), will be a significant growth driver for ...

Venture Global LNG is on track to inaugurate liquefied natural gas (LNG) production at its Plaquemines export plant in ...

LAB eN 2, the drug discovery accelerator launched by Evotec and Novo Nordisk in September 2023, has unveiled its first three ...

The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.

Evotec and Novo Nordisk launched LAB eN² in September 2023 to nurture early research from academic institutions into novel therapeutics.

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...

With Eli Lilly's diabetes and obesity products Mounjaro and Zepbound booming in popularity, the drugmaker finds itself in a ...

The Japanese company's shares hit a new closing high, driven by growing hopes for its games segment and other entertainment businesses. The companies said production is planned to start by end of 2026 ...

As demand for obesity drugs like Wegovy, Zepbound, Mounjaro and Ozempic, outpaces supply, online scams are rising, according to cybersecurity experts.

To receive the full newsletter in your inbox for free sign up here) An experimental immunotherapy drug is a potentially effective treatment for patients with bladder cancer who no longer respond to ...